The traditional view of age-related memory loss focuses on brain-intrinsic damage: neuronal death, amyloid plaques, tau tangles, neuroinflammation. This study proposes a radically different model: the brain loses its ability to "listen" to the body. As we age, the gut microbiome shifts toward species like Parabacteroides goldsteinii that produce medium-chain fatty acids (MCFAs). These metabolites activate GPR84 on peripheral myeloid cells, triggering TNF and IL-1β production via the NLRP3 inflammasome. The resulting local inflammation in the gut and mesenteric adipose tissue silences vagal afferent neurons — the very neurons that relay interoceptive signals from the gut to the hippocampus via the nucleus tractus solitarii (NTS). Without this vagal input, hippocampal neurons fail to activate properly, engram formation collapses, and memory declines.
The beauty of this model is its complete reversibility. Every node in the cascade was validated as a therapeutic target: phage therapy to reduce P. goldsteinii, GPR84 inhibitors to block myeloid activation, anti-TNF/anti-IL-1β antibodies to block cytokines, capsaicin to stimulate vagal neurons, and even GLP-1 receptor agonists like liraglutide to restore hippocampal function. This is not a neurodegenerative dead end — it's a treatable peripheral inflammation problem.
1. Co-housing: Young mice co-housed with 18-month-old mice for 1 month acquired an aged microbiome and lost NOR + Barnes maze performance.
2. FMT: Germ-free mice receiving aged donor microbiota replicated the cognitive deficit without social contact.
3. Germ-free aging: Germ-free mice showed delayed cognitive decline, retaining memory at 18 months.
4. Antibiotics: Broad-spectrum ABX before/during/after co-housing prevented or reversed memory loss within 2 weeks — even in naturally aged mice.
Brain aging is partly peripheral. You don't need brain inflammation to get memory loss — gut inflammation alone is sufficient.
Interoception ≠ just hunger signals. Vagal gut-brain communication directly feeds hippocampal engram formation.
GLP-1 drugs may protect cognition. Liraglutide restored memory in aged mice, explaining emerging epidemiological data on GLP-1 RA and dementia risk reduction.
Microbiome age ≠ host age. A young mouse with an old microbiome thinks like an old mouse. Microbiome rejuvenation may be sufficient to restore cognitive function.
| Kingdom | Bacteria |
| Phylum | Bacteroidota |
| Class | Bacteroidia |
| Order | Bacteroidales |
| Family | Tannerellaceae |
| Genus | Parabacteroides |
| Species | P. goldsteinii |
| Gram stain | Gram-negative, anaerobic |
| LPS | Contains MCFA in lipid A |
1. Correlative: Abundance increases with age across the full lifespan (longitudinal cohort, n=15 C57BL/6). Confirmed by both metagenomic sequencing and stool proteomics.
2. Transmissible: Transferred to young mice by co-housing and FMT. Young mice from facilities with naturally high P. goldsteinii show reduced memory.
3. Sufficient: Mono-colonization of germ-free or ABX-treated mice with P. goldsteinii alone induced cognitive impairment (NOR).
4. Specific: Alistipes, Lachnospiraceae, and Lactobacillus did NOT impair cognition despite similar age-related changes.
5. Mechanistic: Culture supernatants (<3 kDa fraction) are sufficient. The active molecule is 3-HOA (and other MCFAs).
| Metabolite | Formula | Chain | Detection | Cognitive Effect | GPR84 Agonism |
|---|---|---|---|---|---|
| 3-Hydroxyoctanoic acid (3-HOA) | C₈H₁₆O₃ | C8 | Metabolomics | Impairs NOR + FOS | Strong |
| Decanoic acid (Capric) | C₁₀H₂₀O₂ | C10 | Water-insoluble | Impairs NOR + vagal | Strong |
| Dodecanoic acid (Lauric) | C₁₂H₂₄O₂ | C12 | Water-insoluble | Impairs NOR | Moderate |
MCFAs increase in the gut lumen with age (conventional mice only, not GF or ABX-treated). They accumulate in mesenteric and inguinal adipose tissue where they trigger GPR84-dependent inflammation. Importantly, MCFAs do NOT cross the blood-brain barrier — their cognitive effects are entirely peripheral.
| Gene | Gpr84 (EBI2 family) |
| Type | G protein-coupled receptor (GPCR) |
| Ligands | MCFAs (C9–C14), 3-HOA, embelin |
| Expression | Macrophages, monocytes, neutrophils |
| NOT expressed | T cells, B cells, ILCs, neurons, epithelium |
| Downstream | NLRP3 inflammasome, TNF, IL-1β |
| Inhibitor | PBI-4050 (clinical-stage) |
| Agonist | Embelin (experimental) |
| Natural KO | DBA/2 mice (point mutation) |
Step 1: MCFAs bind GPR84 on intestinal macrophages and adipose tissue myeloid cells.
Step 2: GPR84 activation triggers NLRP3 inflammasome assembly. Nlrp3−/− mice are fully resistant to 3-HOA-induced memory loss.
Step 3: NLRP3 cleaves pro-IL-1β into mature IL-1β. TNF is also upregulated.
Step 4: Cytokines accumulate locally in the gut and mesenteric adipose — NOT systemically in blood or brain. This is a peripheral inflammatory event.
Step 5: IL-1β acts on IL-1R1 receptors expressed on PHOX2B⁺ vagal afferent neurons. Conditional deletion of Il1r1 on Phox2b⁺ cells blocks the cognitive effect.
| Approach | Target | Effect on Memory | Type |
|---|---|---|---|
| Gpr84−/− mice | GPR84 | Protected | Genetic KO |
| DBA/2 mice (natural KO) | GPR84 | Protected | Natural variant |
| PBI-4050 | GPR84 | Restored | Pharmacological |
| Embelin (agonist) | GPR84 | Impaired | Pharmacological |
| Nlrp3−/− | NLRP3 | Protected | Genetic KO |
| Anti-TNF antibody | TNF | Restored | Biologic |
| Anti-IL-1β antibody | IL-1β | Restored | Biologic |
| PLX-3397 (CSF1Ri) | All myeloid | Restored | Pharmacological |
| Clodronate liposomes | Peripheral phagocytes | Restored | Pharmacological |
| Ccr2−/− | Peripheral myeloid recruitment | Protected | Genetic KO |
| GPR84−/− → WT chimera | Hematopoietic GPR84 | Protected | BM chimera |
| Phox2bCre-Il1r1fl/fl | IL-1R on vagal neurons | Protected | Conditional KO |
| Marker | Population | Manipulation | Effect on Memory |
|---|---|---|---|
| TRPV1⁺ | Vagal + spinal afferents | Trpv1DTA ablation / hM4Di silencing | Phenocopies aging |
| PHOX2B⁺ | Vagal only (not spinal) | Chemogenetic silencing | Phenocopies aging |
| PHOX2B⁺ TRPV1⁺ | Vagal TRPV1 (most specific) | Intersectional targeting | Phenocopies aging |
| CCKAR⁺ | Gut-innervating vagal | CCK-SAP ablation | Impairs memory |
| Spinal TRPV1⁺ | Spinal afferents | Resiniferatoxin / ganglionectomy | No effect |
The critical population is PHOX2B⁺ TRPV1⁺ vagal afferents innervating the gut. Spinal afferents are not involved. These neurons relay through the nodose ganglion to the nucleus tractus solitarii (NTS), then through the medial septum to the hippocampus.
CA1
CA3
Dentate Gyrus
NTS
φPDS1 Bacteriophage
Targets Parabacteroides. Reduces luminal MCFA levels by altering P. goldsteinii LPS gene expression. Consistent cognitive improvement in aged mice.
Broad-Spectrum Antibiotics
2 weeks of ABX fully restored memory in both co-housed young mice AND naturally aged mice. Prevents and reverses the phenotype.
Young FMT
Implied by reverse experiments: young microbiome → young cognition. GF mice colonized with young donor microbiota show full cognitive capacity.
PBI-4050 (GPR84 inhibitor)
Negated 3-HOA's cognitive effect. Counteracted P. goldsteinii. Restored youthful NOR in aged mice. Already in clinical trials for idiopathic pulmonary fibrosis.
Anti-TNF Antibody
Rescued memory in aged mice, co-housed young mice, and 3-HOA-treated mice. Existing approved drugs: infliximab, adalimumab, etanercept.
Anti-IL-1β Antibody
Protected aged and co-housed young mice. IL-1β signals directly on vagal IL-1R1. Canakinumab already approved for inflammatory diseases.
PLX-3397 (CSF1R inhibitor)
Depletes myeloid cells. Restored cognition in co-housing AND 3-HOA treatment. Approved as pexidartinib for giant cell tumors.
Clodronate Liposomes
Depletes peripheral phagocytes without crossing BBB. Rescued 3-HOA effect. Proves brain microglia are NOT involved — the inflammation is entirely peripheral.
Capsaicin (TRPV1 agonist)
Low-dose capsaicin rescued NTS activation, hippocampal FOS, and memory in BOTH aged and co-housed mice. Overcame P. goldsteinii effect. Requires TRPV1⁺ neurons.
DREADD Chemogenetic Activation
Chemogenetic activation of TRPV1⁺ neurons fully restored hippocampal FOS and NOR in co-housed young mice. Even overcame IL-1β administration.
CCK (Cholecystokinin)
Peripheral CCK administration made aged/co-housed mice cognitively indistinguishable from young controls. Restores hippocampal FOS. Requires TRPV1⁺ neurons. Also overcomes TNF effect.
Liraglutide (GLP-1 RA)
GLP-1 receptor agonist enhanced memory in aged mice. GLP-1 itself restored cognition via vagal activation. Major implications for semaglutide/liraglutide cognitive benefits.
- Thaiss, C.A. et al. Intestinal interoceptive dysfunction drives age-associated cognitive decline. Nature (2026). doi:10.1038/s41586-026-10191-6
- Cryan, J.F. & Dinan, T.G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701–712 (2012).
- de Araujo, I.E. et al. Food reward in the absence of taste receptor signaling. Neuron 57, 930–941 (2008).
- Boehme, M. et al. Microbiota from young mice counteracts selective age-associated behavioral deficits. Nat. Aging 1, 666–676 (2021).
- D'Amato, A. et al. Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity. Gut 69, 2164–2172 (2020).
- Suarez, A.N. et al. Gut vagal sensory signaling regulates hippocampus function through multi-order pathways. Nat. Commun. 9, 2181 (2018).
- Josselyn, S.A. & Tonegawa, S. Memory engrams: Recalling the past and imagining the future. Science 367, eaaw4325 (2020).
- Wood, S.J. et al. GPR84 mediates inflammation-induced myeloid cell activation. J. Immunol. 195, 1092–1102 (2015).
- Reczynska, D. et al. Medium-chain fatty acids modulate innate immune responses. Immunology 168, 542–555 (2023).
- Han, W. et al. A neural circuit for gut-induced reward. Cell 175, 665–678 (2018).
- Kaelberer, M.M. et al. A gut-brain neural circuit for nutrient sensory transduction. Science 361, eaat5236 (2018).
- Matsumoto, M. et al. Impact of intestinal microbiota on intestinal luminal metabolome. Sci. Rep. 2, 233 (2012).
- Franceschi, C. et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. N.Y. Acad. Sci. 908, 244–254 (2000).
- Batista, C.R.A. et al. Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration. Int. J. Mol. Sci. 20, 2293 (2019).
- Drucker, D.J. GLP-1 receptor agonists and the brain: does neuroprotection extend to neurodegenerative diseases? Nat. Rev. Drug Discov. 23, 1–16 (2024).
- Swanson, K.V. et al. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).
- Bäckhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).
- Clemente, J.C. et al. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258–1270 (2012).
- Nøhr, M.K. et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154, 3552–3564 (2013).
- Villumsen, M. et al. GLP-1 based therapies and disease course of neurodegenerative disorders: protocol for a network meta-analysis. BMJ Open 14, e078489 (2024).